Literature DB >> 1358127

General pharmacology of clozapine.

D M Coward1.   

Abstract

Clozapine shows neuroleptic-like inhibition of locomotor activity and conditioned avoidance responding in rodents, although tolerance develops on repeated treatment. EEG-based studies show strong arousal-inhibiting activity of clozapine as well as neuroleptic-like effects on both caudate spindle duration and rat sleep-waking patterns. Effects such as apomorphine blockade, catalepsy and strong increases of plasma prolactin levels are not seen, however, and chronic treatment does not lead to dopamine D2 receptor supersensitivity. Binding studies show clozapine's highest affinities to be for dopamine D4, 5-HT1C, 5-HT2, alpha 1, muscarinic and histamine H1 receptors, but moderate affinity is also seen for many other receptor subtypes. Microdialysis studies indicate a preferential interaction with striatal D1 receptors, whereas autoradiographical studies indicate upregulation of D1 and downregulation of 5-HT2 receptors after chronic clozapine. Clarification of the mechanisms underlying clozapine's special attributes is often hampered by a failure to examine compounds which show a close chemical relationship to clozapine, but which produce extrapyramidal side-effects in man, such as clothiapine, loxapine and amoxapine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358127

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  46 in total

1.  Optimization of a mathematical topological pattern for the prediction of antihistaminic activity.

Authors:  M J Duart; R García-Domenech; G M Antón-Fos; J Gálvez
Journal:  J Comput Aided Mol Des       Date:  2001-06       Impact factor: 3.686

2.  Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Authors:  John A Allen; Julianne M Yost; Vincent Setola; Xin Chen; Maria F Sassano; Meng Chen; Sean Peterson; Prem N Yadav; Xi-ping Huang; Bo Feng; Niels H Jensen; Xin Che; Xu Bai; Stephen V Frye; William C Wetsel; Marc G Caron; Jonathan A Javitch; Bryan L Roth; Jian Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

3.  Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps.

Authors:  Catalin V Buhusi; Warren H Meck
Journal:  Behav Processes       Date:  2006-10-14       Impact factor: 1.777

4.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

Review 5.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

6.  Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm.

Authors:  Min Feng; Nan Sui; Ming Li
Journal:  Behav Brain Res       Date:  2012-10-23       Impact factor: 3.332

Review 7.  Classics in chemical neuroscience: clozapine.

Authors:  Cody J Wenthur; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2013-07-17       Impact factor: 4.418

8.  Meclizine enhancement of sensorimotor gating in healthy male subjects with high startle responses and low prepulse inhibition.

Authors:  José A Larrauri; Lisalynn D Kelley; Mason R Jenkins; Eric C Westman; Nestor A Schmajuk; M Zachary Rosenthal; Edward D Levin
Journal:  Neuropsychopharmacology       Date:  2013-09-18       Impact factor: 7.853

9.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

10.  Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine.

Authors:  V P Bakshi; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.